Europe Generic Drugs Market Size, Share, Analysis, Industry Report and Forecast 2020-2026
Europe generic drugs market is estimated to grow at a CAGR of nearly 5.7% during the forecast period. European government initiatives to support generic producers are supporting to drive market growth. In May 2019, the European Union (EU) is taking measures to increase the competitiveness of EU manufacturers of generic drugs and biosimilar products. EU-based producers of generics and biosimilars will be entitled to produce a biosimilar or a generic version of a supplementary protection certificate (SPC)-protected drug. The new EU regulation will allow manufacturers of generic drugs that are EU based to compete with non-EU manufacturers equally. This will generate high-value jobs and increase the accessibility of generic medicines within the EU.
To Request a Sample of our
Report on Europe Generic Drugs Market:
https://www.omrglobal.com/request-sample/europe-generic-drugs-market
Additionally, in November
2020, the European Commission makes a draft that intends to make it easier for
patients to gain access to low-cost, generic medicines. This draft could cut
the revenues of major pharma companies. The European Commission will consider
targeted policies that facilitate higher competition in generic and biosimilar.
Removal of barriers that delays the entry of generic medicines is also expected
to witness by 2022. Such kinds of initiatives will further escalate market
growth.
Scope of the Europe Generic Drugs Market
Market Coverage
·
Market number available for 2019-2026
·
Base year- 2019
·
Forecast period- 2020-2026
·
Segment Covered- By Application and Route of
Administration
·
Countries Covered- UK, Germany, France, Spain,
Italy, and Rest of Europe
·
Competitive Landscape- Mylan N.V., Teva
Pharmaceutical Industries Ltd., Lupin Ltd., and Novartis International AG
Recent Strategic
Initiatives in the Europe Generic Drugs Market
·
In November 2020, the European Medicine Agency’s
(EMA) declared that it recommends granting marketing authorization for the
generic drug Lenalidomide Mylan (lenalidomide). This hard capsule is indicated
to treat follicular lymphoma and multiple myeloma. It is a generic version of
Celgene’s Revlimid, approved in the European Union (EU) since 2007.
·
In July 2019, Sandoz, a part of Novartis
International AG declared the introduction of the generic cancer drug gefitinib
which is intended for adult patients suffering from locally advanced or
metastatic non-small cell lung cancer. It is available in 13 countries across
Europe and the company will constantly widen to other countries through a
phased rollout.
A full Report of Europe
Generic Drugs Market is Available at: https://www.omrglobal.com/industry-reports/europe-generic-drugs-market
Europe Generic
Drugs Market-Segmentation
By Application
·
Cancer
·
CVD
·
Musculoskeletal Diseases
·
Infectious Diseases
·
Neurology
·
Diabetes
·
Others
By Route of Administration
·
Oral
·
Topical
·
Injectable
·
Inhaler
Europe Generic Drugs Market– Segment by
Country
·
Germany
·
UK
·
France
·
Spain
·
Italy
Rest of Europe
Company Profiles
·
Alvion Pharmaceuticals P.C
·
Fresenius SE & Co. KGaA
·
GlaxoSmithKline plc
·
Hikma Pharmaceuticals PLC
·
Lupin Ltd.
·
Mylan N.V.
·
Novartis International AG
·
Novo Nordisk A/S
·
StadaArzneimittel AG
·
Teva Pharmaceutical Industries Ltd.
Reasons to buy from us –
1.
We cover more than 15 major industries, further segmented into more than 90
sectors.
2.
More than 120 countries are for analysis.
3.
Over 100+ paid data sources mined for investigation.
4.
Our expert research analysts answer all your questions before and after
purchasing your report.
For
More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/europe-generic-drugs-market
About Orion
Market Research
Orion Market Research (OMR) is a market research and consulting
company known for its crisp and concise reports. The company is equipped with
an experienced team of analysts and consultants. OMR offers quality syndicated
research reports, customized research reports, consulting and other
research-based services.
Media
Contact:
Company
Name: Orion Market Research
Contact
Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
Comments
Post a Comment